Li-Yi Zhang

Key Laboratory of Breast Cancer in Shanghai

H指数:30

被引数:3,236

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Restoring the CD226 in CD8+T cells overcomes TIGIT-refractory immunity in HER2+ breast cancer

恢复CD8+T细胞中的CD226可克服HER2+乳腺癌中TIGIT抗性免疫

Cell Death & Disease

IF9.6

2026-07-130

OAAI

Abnormally expressed lncRNAs as potential biomarkers for schizophrenia and positive symptoms

异常表达的lncRNAs作为精神分裂症和阳性症状的潜在生物标志物

Science Progress

IF2.9

2025-10-210

XBP1s Mediates Cross-resistance to Combination Treatment of CDK4/6 Inhibitors plus Endocrine Therapy in Breast Cancer

XBP1s 介导乳腺癌中 CDK4/6 抑制剂联合内分泌治疗产生交叉耐药

ADVANCED SCIENCE

IF14.1

2025-09-010

OAAI

Ferrous Iron Metabolism Modulator for Immune Stress Regulation and Its Application in Skin Allograft Models

二价铁代谢调节剂在免疫应激调节及其在皮肤同种异体移植模型中的应用

Journal of the American Chemical Society

IF15.6

2025-07-140

PRE

Prenatal diagnosis and ex utero intrapartum therapy for congenital epulis

先天性龈突的产前诊断及宫外产时治疗

Asian Journal of Surgery

IF3.8

2025-04-240

Bibliometric analysis of global research on dialectical behavior therapy from 1987 to 2024

1987年至2024年辩证行为疗法全球研究的文献计量分析

FRONTIERS IN PSYCHOLOGY

IF2.9

2025-02-200

LINC01235 Promotes Clonal Evolution through DNA Replication Licensing-Induced Chromosomal Instability in Breast Cancer

LINC01235通过DNA复制许可诱导的染色体不稳定促进乳腺癌的克隆进化

ADVANCED SCIENCE

IF14.1

2025-02-140

OAAI

Ileal perforation caused by intrauterine device displacement

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

IF8.4

2024-10-010

PRE

Anti-TIGIT upregulate CD226 on CD8+T cell as a potential therapeutic manner in HER2 positive breast cancer

CANCER RESEARCH

IF16.6

2024-05-020

PRE

CRTAM promotes antitumor immune response in triple negative breast cancer by enhancing CD8+T cell infiltration

INTERNATIONAL IMMUNOPHARMACOLOGY

IF4.7

2024-03-013

OAAI

Correlation between the expression of JCAD in plasma exosomes and breast cancer

CANCER RESEARCH

IF16.6

2023-03-010

PRE

UBE2E3 promotes the progression of HER2-positive breast cancer and influences the efficacy of targeted therapy via EGFR stabilization

CANCER RESEARCH

IF16.6

2023-03-010

PRE

P95HER2 Expression in HER2-Positive Breast Cancer

CANCER RESEARCH

IF16.6

2023-03-010

PRE

Elevated TCEAL9 Expression Is Correlated With Trastuzumab-based Neoadjuvant Chemotherapy Resistance In HER2-positive Breast Cancer

CANCER RESEARCH

IF16.6

2023-03-010

PRE

MNX1 promotes tumor sensitivity to HER2-targeted therapy in HER2-positive breast cancer

CANCER RESEARCH

IF16.6

2023-03-010

PRE

A single center retrospective analysis of 259 cases of metaplastic breast cancer

CANCER RESEARCH

IF16.6

2023-03-010

PRE

scRNA-seq profiling reveals different tumor immune-microenvironment in triple negative breast cancer and decodes pivotal role of THBS1-SDC1 axis in tumor metastasis

CANCER RESEARCH

IF16.6

2023-03-010

PRE

LINC00478-derived novel cytoplasmic lncRNA LacRNA stabilizes PHB2 and suppresses breast cancer metastasis via repressing MYC targets

JOURNAL OF TRANSLATIONAL MEDICINE

IF7.5

2023-02-1310

OAAI

Achieving T-Type Photochromism through Generating Copper(I) Metallacyclopentadiene Biradical

CCS CHEMISTRY

IF9.2

2022-12-072

PRE

Immunosuppressive lncRNA LINC00624 promotes tumor progression and therapy resistance through ADAR1 stabilization

JOURNAL FOR IMMUNOTHERAPY OF CANCER

IF10.6

2022-10-1715

OAAI

Li-Yi Zhang

个人简介

教育背景

工作经历

荣誉奖项

研究方向